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ABSTRACT
Glucocorticoid receptor (GR) is an essential tran-
scription factor (TF), controlling metabolism, devel-
opment and immune responses. SUMOylation reg-
ulates chromatin occupancy and target gene ex-
pression of GR in a locus-selective manner, but the
mechanism of regulation has remained elusive. Here,
we identify the protein network around chromatin-
bound GR by using selective isolation of chromatin-
associated proteins and show that the network is
affected by receptor SUMOylation, with several nu-
clear receptor coregulators and chromatin modifiers
preferring interaction with SUMOylation-deficient GR
and proteins implicated in transcriptional repression
preferring interaction with SUMOylation-competent
GR. This difference is reflected in our chromatin
binding, chromatin accessibility and gene expres-
sion data, showing that the SUMOylation-deficient
GR is more potent in binding and opening chromatin
at glucocorticoid-regulated enhancers and inducing
expression of target loci. Blockage of SUMOylation
by a SUMO-activating enzyme inhibitor (ML-792) phe-
nocopied to a large extent the consequences of GR
SUMOylation deficiency on chromatin binding and
target gene expression. Our results thus show that
SUMOylation modulates the specificity of GR by reg-
ulating its chromatin protein network and accessibil-
ity at GR-bound enhancers. We speculate that many
other SUMOylated TFs utilize a similar regulatory
mechanism.
INTRODUCTION
Glucocorticoid receptor (GR) belongs to the nuclear re-
ceptor (NR) family and it functions as key transcription
factor (TF) by mediating the effects of glucocorticoids in
metabolism, development and immune response through-
out the human body (1,2). Synthetic GR agonists are widely
used pharmaceuticals due to their potent anti-immune ef-
fects (3). Glucocorticoids are also a central component of
the therapy regimen for patients with GR positive lymphoid
cancers, such as B cell acute lymphoblastic leukemia (B-
ALL) (4). Upon binding to its agonist, GR translocates to
the nucleus where it binds to gene enhancers to modulate
their transcriptional state. To regulate genes, GR needs to
interact and cooperate with coregulator proteins that, based
on in vitro assays, are classically categorized as coactiva-
tors and corepressors. Functionally they act by (i) bridging
the enhancer-bound TF to the RNA polymerase II (Pol2)
machinery, (ii) promoting chromatin remodeling by sliding,
switching or evicting nucleosomes or (iii) covalently modi-
fying amino acids of histones and other proteins (5,6) to reg-
ulate chromatin accessibility or TF activity. However, unbi-
ased investigations of protein networks around chromatin-
bound GR are scarce.
Small ubiquitin-related modifier (SUMO) is a bulky
covalent modification that targets especially nuclear pro-
teins, including a number of physiologically important TFs.
Mammalian cells express three SUMO isoforms SUMO1,
-2 and -3, ca. 100-amino-acid proteins that can be conju-
gated to specific lysine residues on target proteins. SUMO2
and SUMO3 are nearly (97%) identical (herein collec-
tively referred to as SUMO2/3), whereas SUMO1 has only
∼50% identity with SUMO2/3 (7,8). SUMOs activated by
SAE1/2 heterodimer are conjugated to target lysines by
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UBC9. SUMO ligases, such as PIAS proteins, can assist
SUMOylation by guiding the target residue to the active
site of the UBC9 (9). The modification is highly reversible:
SUMO-specific proteases (SENPs) rapidly cleave SUMOs
from target proteins, releasing free SUMO for a new cycle
of conjugation (10). Components of SUMO pathway, such
as PIAS proteins, are previously recognized coregulators for
NRs and other TFs (11).
In vitro studies have linked SUMOylation to transcrip-
tional repression through the recruitment of corepres-
sors (12), but recent unbiased genome-wide studies have
shown that SUMOylation regulates chromatin occupancy
of many key TFs at enhancers, targeting gene expression
in a more versatile and site-specific manner (13–17). How-
ever, the molecular mechanism(s) by which SUMOylation
influences TF binding/occupancy on chromatin have re-
mained uncovered. In this work, by using chromatin im-
munoprecipitation with selective isolation of chromatin-
associated proteins (ChIP-SICAP) and mass spectrome-
try (MS) from cells stably isotopically-labeled with amino
acids in culture (SILAC) (18), we firstly uncover the com-
position of the chromatin protein network around the
hormone-bound GR, which markedly overlaps with the fac-
tors important for the growth of B-ALL cells (19). Sec-
ondly, we show that the protein network is modulated by
the SUMOylation status of GR. The effect of SUMOy-
lation is reflected in our ATAC-seq, ChIP-seq and RNA-
seq data, showing that SUMOylation affects chromatin
accessibility and GR binding at glucocorticoid-regulated
enhancers and thereby expression of GR target genes.




For generation of pcDNA5/TO/FRT-3x-FLAG-PIAS1
complementary cDNA from CMV-3x-FLAG-PIAS1
was inserted as BamHI fragments into pcDNA5/TO
(Invitrogen) backbone. For generation of N-terminally
BirA*-tagged GR3KR (pcDNA5-FRT-TO-HA-BirA-
GR3KR), cDNA of the human GR isoform alpha mutant
(K277,293,703R) (20) was transferred with Gateway-
cloning (Invitrogen) to the destination vector pcDNA5-
FRT-TO-HA-BirA-GW (gift from Dr. Maria Vartiainen,
University of Helsinki, Finland) as previously described
(21). For generation of the N-terminally EGFP-tagged
NCOA1, cDNA of the human NCOA1 isoform SRC1a
from pSG5-SRC1a (22) (gift from Dr. Parker, Imperial
Cancer Research Fund, London, UK) was transferred with
Gateway-cloning (Invitrogen) to the destination vector
pDest-C1-EGFP-GW (gift from Dr. Maria Vartiainen,
University of Helsinki, Finland). The cloning services of
the Genome Biology Unit (GBU) at the University of
Helsinki were used for generation of the N-terminally
mCherry-tagged GRwt and GR3KR constructs. Briefly,
cDNA of the human GR isoform alpha and its 3KR mu-
tant were transferred with Gateway-cloning (Invitrogen)
to the destination vector mCherry-GW. All plasmids were
verified by sequencing.
Antibodies
Anti-GR (sc-1003), IgG (sc-2025, used as a ChIP-seq con-
trol) and anti-GAPDH (sc-25778) were from Santa Cruz
Biotechnology (Santa Cruz, CA, USA); anti-SUMO2/3
(M114-3, used for ChIP-seq and western blotting) was from
MBL International Corporation (Woburn, MA, USA);
anti-PIAS (ab77231) (recognize PIAS1 and PIAS2) and
anti-H3K4me2 (ab7766) were from Abcam (Cambridge,
UK); anti-RNA polymerase II (Pol2) (8WG16, MMS-
126R) from Covance Inc. (Princeton, NJ, USA; cur-
rently from BioLegend, 664906); anti-NCOA1 (A300–
343A) and anti-NCOR1 (A301–145A) from Bethyl Labo-
ratories Inc. (Montgomery, TX, USA); IgG (10400C, used
as a SUMO2/3 IP control) from Life Technologies (Carls-
bad, CA, USA).
Cell lines and culture
Culturing of isogenic HEK293 cells (Flp-In™ -293, Invitro-
gen) stably expressing GRwt (HEK293flpGR) or GR3KR
(HEK293flpGR3KR) was done as previously described
(13). Our previous study (13) confirmed the suitability of
these cell lines to investigate GR SUMOylation. Briefly,
the cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) (Gibco/Invitrogen) supplemented with
10% (v/v) fetal bovine serum (FBS), 25 g/ml penicillin,
25 g/ml streptomycin and 100 g/ml hygromycin-B (In-
vitrogen). Isogenic HEK293 cells (Flp-In 293 T-REx™, In-
vitrogen) expressing in a tetracycline (tet)-inducible man-
ner PIAS1 (HEK293flpPIAS1) were generated accord-
ing to manufacturer’s instructions and as previously de-
scribed (13,23). HEK293flpPIAS1 cells were maintained
as HEK293flpGR cells with additional supplementation
of 15 g/ml blasticidin (Invitrogen). Generation and cul-
turing of HEK293 cells (Flp-In 293 T-REx™, Invitrogen)
expressing in a tet-inducible manner BirA*-GR3KR was
performed according to manufacturer’s instructions and
as previously described (21). The cells were maintained
in DMEM supplemented with 10% (v/v) FBS, 25 g/ml
penicillin, 25 g/ml streptomycin, 50 g/ml hygromycin-
B and 15 g/ml blasticidin. The tet-inducible BirA*-GRwt
-expressing HEK293 cells were maintained as the BirA*-
GR3KR cells. Cells were routinely tested for mycoplasma
contamination. In all experiments, cells were grown in
DMEM supplemented with 2.5% (v/v) charcoal-treated
FBS (steroid-depleted medium) before treatments with 100
nM dexamethasone (Dex, Sigma-Aldrich).
ChIP-SICAP sample preparation
HEK293flpGR or HEK293flpGR3KR cells were grown
in 10-cm dishes in SILAC labeled growth DMEM, high
glucose, no glutamine, no lysine, no arginine (LIFE
Technologies/Thermo Fisher Scientific, A1443101)
supplemented with dialyzed 10% FBS (LIFE Tech-
nologies, 26400044) containing standard Glutamax,
penicillin/streptomycin and Na-pyruvate. The proper
amino acids were added to the corresponding medium at
the final concentration of 84 g/ml (for Arg) and 146 g/ml
final concentration (for Lys). Mixture of vehicle (ethanol,
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cells were metabolic labeled with light SILAC (Arg 0 and
Lys 0, Sigma-Aldrich, A8094 and L8662), Dex-treated
HEK293flpGR cells were labeled with medium SILAC
(Arg 6 and Lys 4, Sigma-Aldrich, 643440 and 616192), and
Dex-treated HEK293flpGR3KR cells were labeled with
heavy SILAC (Arg10 and Lys8, Sigma-Aldrich, 608033
and 608041). GR interactomes from vehicle-treated cells
were assumed not to differ between the cell lines, because
the GR is not chromatin-bound in the absence of ligand
and the ChIP-SICAP primarily identifies chromatin-bound
interactors. Cells were treated with 100 nM Dex or ve-
hicle 2 h before performing ChIP. Cells were crosslinked
for 10min with 1% formaldehyde, crosslinking stopped
with 120 mM glycine for 10min, and cells lysed in RIPA
buffer (0.1% SDS, 0.5% Na-deoxycholate, 0.5% NP-40 in
PBS 1×) for 10min on ice. Chromatin preparation and
ChIP were performed as described for ChIP-seq with 2 g
of anti-GR antibodies followed by capture of on-chromatin
GR interactors as described in (18). Briefly, 3′-ends of
sheared DNA were in vitro biotinylated through terminal
deoxynucleotidyl transferase (ThermoFisher Scientific
EP0161) and used as bait in streptavidin pull down. Tryptic
protein digestion was performed on streptavidin beads
and the resulting peptides were subjected to peptide SP3
de-salting (24,25) before MS analysis.
MS analysis of ChIP-SICAP samples
Peptides were eluted in trifluoroacetic acid (TFA) 0.1% and
then loaded on a trap column (PepMap100 C18 Nano-Trap
2 cm × 100 m) followed by separation over a 50cm ana-
lytical column (Acclaim PepMap RSLC, 75 m × 2 m)
using a 70 min linear gradient of acetonitrile from 6 to
40% (Thermo EasynLC 1200, Thermo Fisher Scientific).
Peptides were analyzed on a Tri-Hybrid Orbitrap Fusion
mass spectrometer (Thermo Fisher Scientific) operated in
data dependent acquisition mode with HCD fragmenta-
tion. The MS1 and MS2 scans were acquired in the Or-
bitrap and ion trap, respectively. Raw data were analyzed
with MaxQuant version 1.5.1.2 based on the Andromeda
search Engine (26,27) and peptide identification was per-
formed using Uniprot database of Human (canonical). Pro-
tein and peptide FDR were set to 1%. Methionine oxidation
and N-terminal acetylation were set as variable modifica-
tions, while carbamidomethylation of cysteine residues was
set as fixed modification. Match between runs, second pep-
tide and re-quantify options were active and both label-free
quantification (LFQ) and intensity-based absolute quantifi-
cation (iBAQ) scores were calculated. Only proteins with
at least 1 unique peptide in both replicates were used for
further processing steps. GR was retrieved among the top
15 proteins in each replicate according to the iBAQ scores.
Proteins with iBAQ scores higher than GR included his-
tones, abundant non-histone chromatin proteins (HMGN1,
HMGN2, HMGB1), fc receptor-like protein 3 (FCRL3),
ubiquitin and SUMO2 (Supplementary Table S1).
Statistical analyses of ChIP-SICAP MS data
Bioconductor package Linear Models for Microarray Data
(limma, version 3.42.2) (28) within R (www.R-project.
org) was used to determine differentially enriched pro-
teins in ChIP-SICAP data by using log2(FC) SILAC-
ratios from two biological replicates as input. The P-values
were adjusted using Benjamini–Hochberg method. For de-
termining Dex-induced interactors of the GRwt (M/L)
or GR3KR (H/L), proteins with adjusted P-value <0.05
were considered as significantly Dex-induced. For proteins
without light value the ratio was imputed with the con-
stant 50, which corresponds to 5.64 upon log2 transfor-
mation. When interactor enrichment in GRwt was com-
pared with GR3KR (H/M), distributions of the ratios were
normalized by the median. Normalized ratios were used
as input for statistical analysis with limma, and proteins
with adjusted P-value <0.05, log2(H/M) <0 were con-
sidered GRwt-enriched and with adjusted P-value <0.05,
log2(H/M) >0 GR3KR-enriched. For proteins without
medium or high value the ratio was imputed with the con-
stant 50 or 0.02, respectively, which correspond to 5.64 or
–5.64 upon log2 transformation, respectively. Selected pub-
lications were used to determine composition of protein
groups and complexes (29–35). Physical interactions be-
tween complex subunits were acquired from the STRING
database (36) and complexes visualized with Cytoscape
(37).
Analysis of SUMO2/3 targets
HEK293 cells expressing in a tet-inducible manner BirA*-
GRwt were grown on 15-cm dishes (3 × 106 cells per
dish) for 3 days after which the medium was replaced with
steroid-depleted medium. After growing in steroid-depleted
medium for 24 h, cells were treated with 30 ng/ml tet for
the next 22 h, after which 100 nM Dex or vehicle (EtOH)
was added for 2 h before harvesting. When harvesting,
20 mM final concentration of N-ethylmaleimide (NEM,
E3876, Sigma-Aldrich) was added to the medium to inhibit
de-SUMOylation. Cell lysis and immunoprecipitation with
anti-SUMO2/3 were performed as described (38). Briefly,
∼5 × 108 cells were lysed, lysates sonicated with a probe
sonicator and supplemented with 50 mM dithiothreitol.
Lysates were boiled at 97 ◦C for 10 min, diluted with RIPA
buffer and supplemented with 10 mM NEM, centrifuged
at 16 000 × g for 15 min at 4 ◦C and supernatants fil-
trated through 0.45 m membrane. SUMO2/3 antibody
produced in-house as described (38) and normal mouse
IgG (Life Technologies) were coupled to protein G agarose
beads (5015952001, Roche Diagnostics) and lysates incu-
bated with antibody-coupled beads 16 h at 4 ◦C. The beads
were rigorously washed, and proteins eluted twice with 0.5
mg/ml SUMO2 epitope peptide (IRFRFDGQPI, Panatecs
Biochemical Solutions, Germany). Eluates were combined
and analyzed by MS.
MS analysis of SUMO2/3 targets and GR3KR BioID sam-
ples
BioID samples of GR3KR were prepared as described (21)
MS analyses were performed on Orbitrap Elite hybrid mass
spectrometer coupled to EASY-nLC II -system using the
Xcalibur version 2.7.0 SP1 (Thermo Fisher Scientific). Pro-
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with SEQUEST search engine (version 1.4, Thermo Sci-
entific). Thermo .raw files were searched against the hu-
man component of the UniProt-database complemented
with trypsin, BSA and tag sequences. Trypsin was used as
the enzyme specificity. Search parameters specified a pre-
cursor ion tolerance of 15 ppm and fragment ion toler-
ance of 0.8 Da, with up to two missed cleavages allowed
for trypsin. Carbamidomethylation of cysteine residues was
used as static modification whereas oxidation of methio-
nine and biotinylation (only for BioID samples) of lysine
residues or N-terminus were used as dynamic modification.
Peptide FDR was calculated using Percolator node of soft-
ware and set to <0.01. Spectral counting was used to pro-
duce semiquantitative data.
Statistical analyses of SUMO2/3 and GR BioID MS data
Significance analysis of interactome (SAINTexpress)
(39,40) was used to determine significantly enriched
proteins. In SUMO2/3 IP experiments, significantly
SUMOylated proteins were determined by setting the IgG
sample as the control and Dex and vehicle samples as
the experiment. To determine enrichment of SUMO2/3
targets in Dex, the vehicle samples were set as the control.
Proteins with FDR <0.05 were considered as significantly
enriched in each comparison. SAINTexpress output files
from SUMO2/3 IP are in Supplementary Table S2. In
BioID experiments, significantly Dex-induced GR3KR
interactors were determined with SAINTexpress by setting
the Dex samples as the experiment and vehicle samples as
the control. Proteins with loose filtering FDR <0.3 were
considered as significantly enriched (Supplementary Table
S3). Western blotting showed that streptavidin affinity-
purified eluates from BirA*-GRwt and BirA*-GR3KR cell
lines contain comparable levels of GR and biotinylated
proteins (Supplementary Figure S5). Keratins, tubulins,
bovine serum albumin and trypsin were considered as
contaminants.
ChIP-seq
Chromatin immunoprecipitation (ChIP) was per-
formed as described (13). Briefly, HEK293flpGR,
HEK293flpGR3KR and HEK293flpPIAS1 cells were
seeded at ∼70% confluence into 10-cm plates and al-
lowed to grow in steroid-depleted transfection medium
for 72 h. HEK293flpGR and HEK293flpGR3KR cells
were treated with vehicle, or Dex (100 nM) for 1 h and
HEK293flpPIAS1 cells with 100 ng/ml of tet for 24 h
prior ChIP. In ML-792 (MedKoo Biosciences Inc., 407886)
experiments, HEK293flpGR and HEK293flpGR3KR cells
were exposed to 1 M ML-792 (or DMSO as control) for
24 h. Subsequently, the cells were treated with vehicle or
Dex (100 nM) for the final 1 h. Chromatin was fragmented
to an average size of 300–500 bp by sonication (Biorup-
tor, UCD-300, Diagenode). Antibodies were coupled to
magnetic protein G beads (Dynabeads, Invitrogen) for 16
h, sonicated lysates were incubated with antibody-coupled
beads for 16 h. Antibodies used per IP: GR, 2 g; NCOR1,
1.4 g; NCOA1, 3 g; Pol2, 1 g, SUMO2/3, 1 g;
H3K4me2, 1 g; PIAS, 1.5 l; IgG, 1 g. Between 2
and 4 IP samples were pooled for one ChIP-seq sample.
ChIP-seq sequencing libraries were generated according
to manufacturer’s protocol using NEBNext Ultra II DNA
Library Prep Kit (E7645L, NEB). In general, two biologi-
cal replicate samples were sequenced using Illumina HiSeq
2000 (50SE) or NextSeq 500 (75SE).
ATAC-seq
ATAC-seq was performed as described (41). Briefly,
HEK293flpGR and HEK293flpGR3KR cells were seeded,
grown and hormone treated as in ChIP-seq. The cells were
detached from the plates using 2 ml of Accutase (Thermo
Fisher Scientific, A6964) by incubating 5 min at RT. Dex-
treated cells were detached with Accutase in the presence
of 100 nM Dex. Accutase was inactivated with 3.5 ml of
growth media. For nuclei isolation, the cell pellets were
resuspended in a concentration of 5 million cells per ml
in Buffer A [15 mM Tris–HCl (pH 8), 15 mM NaCl, 60
mM KCl, 1 mM EDTA, 0.5 mM EGTA, 0.5 mM spermi-
dine (Sigma-Aldrich, S2626), protease inhibitor cocktail].
Subsequently, equal volume of Buffer A with 0.04% (w/v)
IGEPAL (Sigma-Aldrich, I8896) was added, to obtain a
concentration of 2.5 million cells per ml with 0.02% (w/v)
IGEPAL. Samples were incubated on ice for 10 min and
washed two times with Buffer A without IGEPAL. Isola-
tion of nuclei was verified by Trypan Blue counting. Sub-
sequently, the rest of ATAC followed published protocol
(42). Briefly, 100 000 nuclei were subjected to Tn5 transpo-
sition reaction using 2.5 l TDE1 from Nextera DNA Li-
brary Prep Kit (Illumina, FC-121-1030). After adding the
transposition reaction mix, the samples were incubated 45
min at 37◦C with 800 rpm shaking, and subsequently DNA
was purified using MinElute PCR Purification kit (Qiagen,
28004). Transposed DNA was PCR amplified and barcoded
using published primers (42), and NEBNext High-Fidelity
2× PCR Master Mix (New England Biolabs, M0551S). Ap-
propriate number of PCR cycles was determined as de-
scribed (42). After PCR, the samples were size selected
using SPRIselect (Beckman Coulter #B23317) to remove
<150 bp and >800 bp fragments according to manufac-
turer’s instructions. Size selection verification, library con-
centration and size were analyzed using Agilent Bioanalyzer
High Sensitivity DNA Analysis kit (Agilent, 5067-4626).
Two biological replicate samples were sequenced using Il-
lumina NextSeq 500 (40PE).
RNA-seq and data analysis
HEK293flpGR and HEK293flpGR3KR cells were seeded
onto 6-well plates and grown for 48 h, after which the
medium was replaced with steroid-depleted medium. Af-
ter growing in steroid-depleted medium for 24h, the cells
were exposed to 1 M ML-792 (or DMSO control) for 24
h and treated with vehicle or Dex (100 nM) for the last 6
h. RNA was extracted with RNeasy® Plus Mini Kit (Qia-
gen) and mRNA isolated using NEBNext Poly(A) mRNA
Magnetic Isolation Module (E7490, New England Biolabs)
according to manufacturer’s recommendations. RNA-seq
libraries were prepared using NEBNext Ultra II Direc-
tional RNA Library Prep Kit (E7765, New England Bio-
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with Illumina NextSeq 500 (75SE). RNA-seq raw reads
were quality controlled, and adapters and reads smaller
than 36 nt were removed. Trimmed raw reads were aligned
to hg19 genome using STAR (43) with default settings.
Total count per gene was calculated using TPM normal-
ization and differentially expressed genes were analyzed
with DESeq2 using HOMER (44) for all comparisons.
RNA-seq analysis was performed as described (45). Genes
with TPM >0.5 in any treatment were considered as ex-
pressed and those with adjusted P-value of <0.01 and
log2(fold change) of <–0.5 or >0.5 as differentially ex-
pressed. Differentially expressed gene sets were subjected to
pathway analysis with DAVID functional annotation tool
(GOTERM BP DIRECT) (46,47).
ChIP-seq and ATAC-seq data analysis
ChIP-seq data analysis was performed as previously de-
scribed (13,48). For ATAC-seq data, after filtering low qual-
ity reads as with ChIP-seq data analysis, paired-end sam-
ples were aligned to hg19 genome using Bowtie2 (49). Align-
ment was performed with end-to-end sensitive mode allow-
ing no mismatches. Around 20% of the reads were mapped
to mitochondrial DNA. From the two biological repli-
cate sample, at least 50 million unique non-mitochondrial
reads were obtained for each condition. Downstream data
analysis was performed using HOMER (44). Peaks in
each dataset were called using findPeaks with style fac-
tor, FDR <0.01, > 25 tags, >4-fold over control sample
and local background. IgG sample from the background
HEK293flpFRT cells was used as control sample. DESeq2
(50) through getDiffrentialPeaksReplicates.pl was used to
isolate differential binding peaks (FDR < 0.05, fold change
[FC] > 2) between the GRwt and GR3KR (C1–C3). For
determination of pre-bound, Dex-induced, and non-GR
SUMO2/3 sites, SUMO2/3 peaks were called from each
sample as indicated above. Dex-induced SUMO2/3 sites
peaks showed tag FC > 4 Dex/EtOH, and Poisson P-value
<0.0001. SUMO2/3 sites that did not meet these criteria
were classified as non-induced SUMO2/3 sites. Overlap of
non-induced SUMO2/3 and GR peaks defined pre-bound
SUMO2/3 and non-GR SUMO2/3 sites. GR-binding sites
changed upon ML-792 treatment were determined with the
same criteria. For determination of Dex-independent and
-dependent sites, indicated EtOH or Dex ChIP-seq samples
from GRwt and GR3KR cells were combined and peaks
called as indicated above. Dex-dependent peaks showed less
than 1 tag per bp per site at EtOH samples and showed
tag FC > 4 Dex/EtOH, with Poisson P-value <0.0001.
Sites that did not meet these criteria were classified as Dex-
independent sites. The following count of sites were deter-
mined as Dex-independent; 42 977 for NCOA1, 8 584 for
NCOR1 and 89 260 for SUMO2/3. The following count
of sites were determined as Dex-dependent; 67 458 for
NCOA1, 11 848 for NCOR1 and 25 766 for SUMO2/3.
Chromatin accessibility populations were defined on the ba-
sis of FC; Dex-induced sites had FC > 4 and Dex-decreased
FC < 4 Dex/EtOH, with Poisson P-value <0.0001. The
rest of the sites were classified as unresponsive to Dex treat-
ment. Pre-accessible and de novo C2 sites were defined on
the basis of ATAC-seq data. De novo sites had <1.5 log2
tags, while pre-accessible sites had >1.5 log2 tags in EtOH-
treated ATAC-seq sample from GRwt cells. Aggregate plots
and heatmaps were generated with 10 bp or 20 bp bins sur-
rounding ±1 kb area around the center of the peak. All
plots were normalized to 10 million mapped reads and fur-
ther to local tag density, tags per bp per site. Box plots
represented either log2 tag counts or log2 tag count com-
parison of Dex/EtOH. Log2 transformed tag counts were
used in the scatter plots. AnnotatePeaks.pl was used to cal-
culate the enrichment of sites to different genomic loca-
tion; promoter, intron, intergenic, exon and miscellaneous
(other) sites. Miscellaneous sites consist of UTRs and non-
coding RNAs. De novo motif searches were performed us-
ing findMotifsGenome.pl with the following parameters;
200 bp peak size window, strings with 2 mismatches, bino-
mial distribution to score motif P-values, and either 50 000
background regions (GR binding sites) or 250 000 back-
ground regions (ATAC sites) (Supplementary Table S4).
Motif heatmap was generated using hierarchical clustering
with Euclidean distance. Association of GR binding sites to
Dex-regulated genes (peak-centric analysis) was performed
on the basis of linear distance using AnnotatePeaks.pl. C1–
C3 cluster sites were checked against the union of Dex
up-regulated or Dex down-regulated genes in GRwt and
GR3KR cells using RNA-seq data. The log2 Dex/EtOH
induction was shown in box plots. Statistical significance
was determined either with unpaired two-sample t-test (two
samples), or with One-way ANOVA with Bonferroni post
hoc test (three or more samples). Published datasets were
analyzed as indicated above.
FRAP
HEK293 cells were seeded to -slide eight-well cham-
bers (Ibidi) in DMEM supplemented with 2.5% (v/v)
charcoal-treated FBS (steroid-depleted medium) and trans-
fected with constructs expressing EGFP-tagged NCOA1 or
NCOA2 and mCherry-tagged GRwt or GR3KR. Two days
later, cells were induced with 100 nM dex for 1h, and the
nucleus was scanned using 488 and 561 nm excitations at
250-ms intervals with Zeiss LSM 800 microscope. After 20
scans, a high intensity bleach pulse at 488 and at 561 nm
were applied simultaneously to a 1.5-m wide rectangular
area spanning the nucleus and scanning of the nucleus was
continued until equilibrium in fluorescence distribution was
reached. The fluorescence recovery was analyzed from the
bleached area. Measurements with NCOA1 or NCOA2 to-
gether with GR were performed in two individual experi-
ments where a minimum of 10 nuclei were measured in each
experiment.
Public datasets
The following publicly available sequencing datasets were
used: GSE48379 for GR and SUMO-2/3 ChIP-seq
in HEK293flpGR cells, GR and SUMO-2/3 ChIP-
seq in HEK293flpGR3KR cells, and IgG ChIP-seq in
HEK293flpFRT cells (13); GSE32970 for DNase-seq in
HEK293T cells (51); GSE30263 for CTCF ChIP-seq in
HEK293 cells (52); ENCSR000FCH for H3K27ac ChIP-
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ChIP-seq in HEK293 cells (53); ENCSR000FCG for
H3K4me1 ChIP-seq in HEK293 cells (53); GSE35583 for
H3K4me3 ChIP-seq in HEK293 cells (52); GSE91583 for
GFP-ATF2 ChIP-seq in HEK293flp cells (52).
RESULTS
Protein interaction network of the chromatin-bound GR
To better understand the mechanisms by which GR reg-
ulates gene transcription, we applied ChIP-SICAP, which
purifies exclusively chromatin-bound proteins (18) to re-
veal the composition of the protein network around
the chromatin-bound GR (Figure 1A). Medium SILAC-
labelled isogenic HEK293 cells that stably express GR
(HEK293flpGR) (13) were exposed to dexamethasone
(Dex, a synthetic GR agonist), while light SILAC-labelled
cells were treated with ethanol (EtOH, vehicle) before
performing ChIP-SICAP experiment. All samples showed
comparable levels of GR capture in ChIP, retrieving GR
among the most abundantly identified proteins in each sam-
ple (Supplementary Figure S1A). Biological replicates also
showed good correlation between the obtained networks
(Pearson’s r = 0.827) (Figure 1B). ChIP-SICAP identi-
fied 317 (significant with adjusted P-value < 0.05 or im-
puted) Dex-induced GR interactors (i.e. interacting with
the receptor or binding at the same 200–300 bp chro-
matin fragment) as determined by applying moderated t-
statistics with linear model analysis (limma) (28) (Figure
1B). The full list of Dex-induced GR interactors is re-
ported in Supplementary Table S1. Dex-induced interactors
included expected NR coactivators (e.g. NCOA2, EP300
and CREBBP), NR corepressors (e.g. NCOR1, TBL1XR1
and HDAC2), and AP-1 components (JUN and ATF3), as
well as several other transcriptional coregulators and pro-
teins involved in chromatin remodeling. The latter group
includes members of the bromodomain and extra-terminal
motif (BET) family (BRD2 and BRD3/4), chromodomain
helicase DNA-binding (CHD) family (CHD1, CHD4,
CHD7 and CHD8) and different subunits of the BAF
(SWI/SNF) complex (ARID1A, SMARCC1, SMARCC2,
SMARCE1, SMARCD2, DPF2, ACTL6A, SMARCA4
and SMARCA2).
Next, we compared our GR ChIP-SICAP data of Dex-
induced GR interactors with genes that in a genome-wide
RNAi screen influenced the growth and Dex-sensitivity
of NALM-6 cells that model B-ALL (19). Intriguingly,
many of the identified GR chromatin partners were prod-
ucts of genes influencing the growth (116 genes) and Dex-
sensitivity (47 genes) (Supplementary Figure S2) of NALM-
6 cells. These results indicate that many of the GR chro-
matin partners in HEK293 cells have physiologically rele-
vant functions also in B-ALL cells.
GR and many of its chromatin partners are SUMO2/3 tar-
gets
Several studies have shown that GR is modified by
SUMO2/3 in various cell lines (54–63), including HEK293
cells (63) (Supplementary Table S2). To verify this hypoth-
esis in our experimental setup, we employed the protocol
by Barysch et al. (38) with a monoclonal SUMO2/3 an-
tibody to identify SUMO2/3 targets in Dex- and vehicle-
treated HEK293 cells that stably express GR. Significance
analysis of interactome (SAINTexpress) (39,40) identified
450 proteins as significant (FDR < 0.05) SUMO2/3 targets
when compared to the IgG control (Figure 2A). Most of
them (91%) (including all our top 100 SUMO2/3 targets)
have been identified as SUMO2/3 targets in other studies
(54–67) (Supplementary Table S2). Interestingly, ca. 26%
(82 of 317) of Dex-induced GR interactors were identi-
fied as SUMO2/3 targets (Figure 2A). Some of them, such
as TRIM28, TOP2A and TOP2B, were among the most
SUMOylated proteins. SUMOylation of 11 proteins, in-
cluding the GR, was significantly (FDR < 0.05) increased in
response to Dex treatment (Figure 2A, Supplementary Ta-
ble S2), whereas no protein showed reduced modification in
response to Dex. The GR was targeted by SUMO2/3 only
in the presence of Dex, indicating that the binding of ago-
nist triggers the SUMOylation of the receptor.
Next, we performed ChIP-seq with SUMO2/3 antibody
in vehicle and Dex treated HEK293flpGR cells and com-
pared it to our previously published GR cistrome from
HEK293 cells (13) to examine whether the SUMOylation
of GR interactors is reflected on the genome-wide occu-
pancy of SUMO2/3 at GR-binding sites (GRBs). We also
performed ChIP-seq for PIAS SUMO ligases (11) to ex-
amine whether these components of the SUMOylation ma-
chinery are present at the binding sites. In parallel, we
used antibodies against RNA polymerase II (Pol2) and
the active histone mark H3K4me2. Clustering of ChIP-seq
obtained from SUMO2/3 chromatin-binding sites yielded
three clusters: a small cluster of pre-bound SUMO2/3
(GRBs that are already bound by SUMO2/3 prior to Dex
exposure), a cluster of Dex-induced SUMO2/3 (GRBs that
bind SUMO2/3 only after Dex exposure) and a larger clus-
ter of non-GR SUMO2/3 (SUMO2/3-bound sites that do
not bind GR) (Figure 2B). As expected, Dex-induced chro-
matin binding of PIAS proteins mirrored that of SUMO2/3
in HEK293flpGR cells (Figure 2B). In the absence of
Dex, overexpression of PIAS1 (HEK293flpPIAS1 cells) did
not force binding of SUMO2/3 or PIAS to these Dex-
responsive sites, further confirming that their binding is
highly dependent on the activation of GR (Supplementary
Figure S3A). Based on publicly available chromatin acces-
sibility (DNase-seq) and histone modification (ChIP-seq)
data from HEK293 cells, we can speculate that chromatin
sites where Dex induces the binding of SUMO2/3 are less
accessible and harbor less of active histone modifications
(H3K27ac and H3K4me3) compared to other SUMO2/3-
bound sites (Figure 2B, Supplementary Figure S3B). How-
ever, enhancers, marked by H3K4me1, are enriched among
Dex-induced sites compared to non-GR SUMO2/3 sites
(Figure 2B, Supplementary Figure S3B). After Dex in-
duction, an active histone modification H3K4me2 was re-
distributed (Figure 2B, Supplementary Figure S3C) and
the occupancy of Pol2 was increased at the Dex-induced
SUMO2/3 chromatin-binding sites (Figure 2B), both in-
dicative of enhancer activation. Taken together, these find-
ings indicate that a significant fraction of GR chromatin
partners are SUMO2/3 targets and their recruitment to
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Figure 1. GR interacts with various coregulators on chromatin. (A) Schematic representation of the ChIP-SICAP protocol. (B) Scatter plot showing
chromatin-associated proteins identified with GR ChIP-SICAP. Blue dots with blue rim represent significantly (adj. P-value < 0.05) Dex-induced interac-
tions, blue dots with green rim represent imputed Dex-induced interactions and grey dots represent interactions that are not Dex-induced.
This notion is also supported by the identification of
SUMO2 as a Dex-induced GR chromatin partner in ChIP-
SICAP (Figure 1B).
SUMOylation of GR modulates the protein interaction net-
work of the chromatin-bound GR
The main SUMOylated target lysines of the GR (K277 and
K293) are located at KxE (where  is a hydrophobic
residue) SUMO consensus motifs in the N-terminal domain
of the receptor (63), while the C-terminal domain harbors
a weaker SUMO consensus motif-embedded lysine (K703).
We have previously shown that mutation of lysines at the
three SUMO consensus motifs leads to a SUMOylation-
defective GR (GR3KR) that shows enhanced activity in re-
porter gene assays (20), that binds more prevalently to chro-
matin and that harbors a distinct chromatin-binding pat-
tern from the wild-type receptor (GRwt) (13).
To investigate the role of the SUMO target lysines of
GR on the receptor’s on-chromatin interactome, we ap-
plied ChIP-SICAP in heavy-labeled HEK293flp cells ex-
pressing GR3KR (HEK293flpGR3KR) and compared the
interactome to that of GRwt. Western blotting showed that
the cellular expression of GR3KR protein is slightly lower
than that of GRwt (Supplementary Figure S4A and B).
The GR3KR ChIP-SICAP samples were processed in par-
allel with the (above described) GRwt samples in a triple
SILAC experimental setting. Western blotting analysis con-
firmed that GRwt and GR3KR inputs, flow-throughs and
eluates from ChIP contained comparable levels of GR pro-
tein (Supplementary Figure S4C–E). Both GR3KR repli-
cates showed comparable levels of GR capture in ChIP-
SICAP, retrieving GR among the most abundantly identi-
fied proteins (Supplementary Figure S4F). Biological repli-
cates also showed concordant interactomes (Pearson’s r =
0.845) (Supplementary Figure S4G). ChIP-SICAP identi-
fied 342 (significant with adjusted P-value < 0.05 or im-
puted) Dex-induced GR3KR interactors as determined
with limma (Supplementary Figure S4G and H, Supple-
mentary Table S1).
Next, we compared the Dex-induced chromatin part-
ners of GR3KR to GRwt by using the heavy/medium
SILAC ratios. Biological replicates showed concordant in-
teractomes (Pearson’s r = 0.871). Analysis with limma
revealed that, from Dex-induced GR interactors, 102 pro-
teins significantly preferred GRwt (adjusted P-value <
0.05 or imputed, and log2[3KR/wt] < 0), whereas 122
proteins preferred GR3KR (adjusted P-value < 0.05 or
imputed, and log2[3KR/wt] > 0) (Supplementary Table
S1). GRwt-preferred interactors encompassed coactivators
NCOA6 and MED1, but this group of proteins was inter-
estingly more enriched with corepressors or proteins im-
plicated in transcriptional repression, including NCOR1,
IRF2BP2, ZNF536, ZNF608 and ZNF703 (NLZ1) and
BAZ1A (ACF1) (Figure 3A and B, Supplementary Ta-
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Figure 2. GR and its chromatin partners are SUMO2/3 targets. (A) Scatterplot showing proteins identified as significantly SUMOylated (enriched over
IgG, SAINTexpress FDR < 0.05) in SUMO2/3-pulldown in HEK293 cells expressing GR. X-axis shows the effect of Dex on the SUMOylation of each
protein as Log2(Dex/EtOH). Spectral count (Dex) on the y-axis represents relative abundancy of the protein in the anti-SUMO2/3 immunoprecipitates.
Spectral counts were normalized to the total spectral count sum of each sample. Significant (adj. P-value < 0.05) or imputed Dex-induced interactors
identified with GR ChIP-SICAP are shown in blue. Proteins with significantly (FDR < 0.05) increased SUMOylation in Dex compared to vehicle are
shown in red. There were no Dex-induced GR ChIP-SICAP interactors with significantly increased SUMOylation in Dex. (B) Heat maps representing
GR, SUMO2/3, PIAS, Pol2 and H3K4me2 ChIP-seq data from HEK293flpGR (wt) in the presence and absence of Dex, and H3K4me1, H3K4me3 and
H3K27ac ChIP-seq data from HEK293, and DNase-seq (DNase) data from HEK293T cells. Each heat map represents ±1kb around the center of the
SUMO2/3 peak. Binding intensity (tags per bp per site) scale is noted below on a linear scale. All heat maps are normalized to a total of 10 million reads,
and further to local tag density. Clusters represent from top to bottom; GR sites with pre-bound SUMO2/3, GR sites with Dex-induced SUMO2/3 (only
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Figure 3. A number of transcriptional regulators prefer SUMOylation-deficient GR to SUMOylation-competent GR. (A) Scatter plot showing correlation
of on-chromatin GR interactors enriched in GR3KR over GRwt cells in the biological replicates. Only Dex-induced interactions are shown. Blue dots
represent GRwt-enriched interactions (adjusted P-value < 0.05 or imputed, and log2[3KR/wt] < 0), red dots GR3KR-enriched interactions (adjusted P-
value < 0.05 or imputed, and log2[3KR/wt] > 0) and gray dots interactions that are not enriched. (B) Volcano plot representing significance of interactions
that are differentially enriched with GR3KR compared to GRwt. Only Dex-induced interactions are shown. Dot colors are the same as in (A), but imputed
values are not shown. (C) GR interactor enrichment in nuclear protein complexes. Color of each protein represents enrichment in GRwt (blue) compared
with GR3KR (red). Left side of the circle represents interactor enrichment in ChIP-SICAP and right side in BioID data. Proteins in grey belong to the
protein complex but were not found in proteomics data. Interactions between complex subunits were acquired from the STRING database. Edge thickness
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SMARCA2 ATPase subunit, SMARCD2 and DPF2 from
the BAF chromatin remodeling complex, chromatin remod-
eling factor CHD1, BET family chromatin reader BRD2,
topoisomerase II homologues TOP2A and TOP2B, Aurora
kinase B (AURKB), coactivator NCOA1, and JUN and
ATF3 from the AP-1 TF complex (Figure 3A and B, Sup-
plementary Table S1). We next complemented the compar-
ison of the on-chromatin interactome of GRwt and that
of GR3KR by using proximity-dependent biotin identifi-
cation (BioID) which maps protein-protein interactions of
Dex-activated GR in the nuclear space (21). BioID em-
ploys fusion of GR to a mutated Escherichia coli biotin
ligase (BirA*) that covalently attaches biotin to primary
amines within 10 nm range (68). BioID revealed 138 Dex-
induced GR3KR interactors as determined with SAINT-
express (FDR < 0.3) (39,40) (Supplementary Table S3).
Comparison to GRwt BioID data (21) showed that 79 pro-
teins preferred GR3KR over GRwt (FDR < 0.3), whereas
only one protein preferred GRwt (Supplementary Table S3).
Although the ChIP-SICAP and the BioID yielded differ-
ences, notably, the GR3KR-preferred interactions with the
BAF chromatin remodeling complex subunits SMARCA2
and DPF2, CHD1 and ATF3 were also found as GR3KR-
preferred interactions in BioID. Additionally, chromatin re-
modelers CHD7 and CHD8, and ATF1 and ATF7 of the
AP-1 TF complex were GR3KR-preferred interactors in
BioID (Figure 3C, Supplementary Table S3).
Inhibition of SUMOylation using a selective SAE inhibitor
enhances GR chromatin binding and target gene expression
We have previously shown that SUMOylation of GR en-
hances chromatin occupancy and target gene expression of
GR, not at all loci, but in a locus-selective manner (13).
To confirm the results obtained with SUMOylation site-
mutated receptor and that the mutation principally com-
promised the SUMOylation, not other lysine modifica-
tions in the receptor, we utilized a novel potent SUMO-
activating enzyme (SAE) inhibitor ML-792 (69) in ChIP-
seq and RNA-seq experiments. We first re-determined and
clustered the chromatin GR-binding sites (GRBs) from our
previous study (13) (see Materials and Methods for de-
tails) as sites preferred by GRwt (cluster [C]1, blue color),
sites shared by GRwt and GR3KR (C2, black color), and
sites preferred by GR3KR (C3, red color) (Figure 4A, Sup-
plementary Figure S6A-B). We first confirmed by west-
ern blotting with SUMO2/3 antibody that exposure of
HEK293flpGR cells to ML-792 indeed results in a ro-
bust inhibition of protein SUMOylation (Supplementary
Figure S6C). HEK293flpGR and HEK293flpGR3KR cells
were exposed to ML-792 (or DMSO) for 23 h before 1 h
treatment with Dex (or vehicle), and ChIP-seq was per-
formed with GR antibody. In the absence of SUMOylation
inhibitor, GR and GR3KR showed their preferred bind-
ing to C1–C3 GRBs as described previously (Figure 4A
and B). In line with the enhanced chromatin occupancy
of the SUMOylation-deficient GR, inhibition of SUMOy-
lation significantly enhanced the chromatin occupancy of
SUMOylation-competent GR at C1, C2 and C3, result-
ing also in > 3 500 novel GRwt-binding sites (Figure 4A
and B) (Supplementary Figure S6D and E). As expected,
ML-792 was not able augment the chromatin occupancy of
GR3KR, but the inhibitor interestingly weakened the bind-
ing of SUMOylation-deficient receptor at all clusters. The
latter finding suggest an interplay between the SUMOyla-
tion of the receptor and other chromatin proteins in the reg-
ulation of chromatin GR. Cross-comparison of the effect
of GR SUMOylation sites and that of ML-792 on the chro-
matin occupancy of the receptor indicated a large number of
the C3 GRBs with enhanced occupancy of GRwt upon inhi-
bition of SUMOylation (Figure 4C). Examples of genome
browser tracks of GRBs unchanged and induced by ML-
792 are shown in Supplementary Figure S7A–D.
Since inhibition of SUMOylation in GRwt cells blunted
the differences in chromatin binding between GRwt and
GR3KR cells, we next analyzed the effect of ML-792 also
on Dex-regulated gene expression by RNA-seq as described
in Methods. Firstly, RNA-seq analyses recapitulated the
main differences in the Dex-regulated gene expression be-
tween GRwt and GR3KR cells previously measured by
gene arrays (13) (Figure 4D, Supplementary Figure S8A).
For example, FKBP5 and TSC22D3 showed similar Dex
regulation, while CDKN1C and MAFB displayed signifi-
cantly stronger Dex induction by GRwt. ELK1 and CXXC4
in turn showed significantly more robust Dex induction by
GR3KR (13) (Supplementary Figure S8B). In agreement
with the ChIP-seq data, inhibition of SUMOylation in-
creased the number of Dex-regulated genes in GRwt cells
(Figure 4E, Supplementary Figure S8B), whereas the inhi-
bition decreased their number in GR3KR cells (Figure 4F).
Cross-comparison of the effect of GR SUMOylation sites
and that of ML-792 on the target gene expression indicated
that over half of the GR3KR target genes that are also reg-
ulated by ML-792 show enhanced Dex regulation in GRwt
cells upon ML-792 treatment (Figure 4G). Pathway analy-
ses indicated that both GR SUMOylation sites and ML-792
influence expression of genes associated with cell growth
and proliferation processes (Supplementary Figure S8C),
which is in line with the effect of GR SUMOylation sites
on cell growth characteristic and growth response to Dex
(13). Finally, we associated C1–C3 sites (ChIP-seq data) to
Dex-regulated genes (RNA-seq data) (Supplementary Fig-
ure S8D and E). At the C1 sites, the Dex up-regulation
did not significantly differ between the receptor forms, and
ML-792 did not yield any significant effect, whereas the
Dex up-regulation differed at the C2 and C3 sites, with
GR3KR showing stronger Dex induction (Supplementary
Figure S8D). ML-792 enhanced Dex up-regulation at C2
sites in GRwt (P < 0.001) and GR3KR cells (P < 0.05) and
resulted in an increasing trend of Dex induction at C3 sites
in GRwt cells but not in GR3KR cells. Overall, our results
with the SUMOylation inhibitor ML-792 are in line with
the consequences of the GR SUMOylation site mutations,
thus confirming the role of GR SUMOylation in the reg-
ulation of receptor chromatin occupancy and target gene
regulation.
SUMOylation-deficient GR recruits more efficiently
NCOA1, but not NCOR1, to chromatin
Next, we examined whether the differences in the interac-
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Figure 4. SUMOylation inhibitor ML-792 blunts the differences in GR chromatin binding and target gene expression between GRwt and GR3KR cells.
(A) GR ChIP-seq profiles from DMSO- or ML-792-treated HEK293flpGRwt (wt) and HEK293flpGR3KR (3KR) cells in the presence or absence of Dex.
Each heat map represents ±1 kb around the center of the GR peak. C1 represents GRwt-preferred, C2-shared, and C3 GR3KR-preferred binding sites.
Only top 10 000 sites (top 10k) are shown for C2. Binding intensity (tags per bp per site) scale is noted below on a linear scale. All heat maps are normalized
to a total of 10 million reads, and further to local tag density. (B) Box plots representing normalized log2 tag density of ML-792 GR ChIP-seq data at
C1 (blue), C2 (black) and C3 (red) sites. P-values were calculated with one-way ANOVA with Bonferroni post hoc test. All box plots are normalized to
total of 10 million reads. Blue color represents GRwt (wt), red color GR3KR (3KR). (C) Scatter plot representing GR ChIP-seq log2 tag density of ML-
792/DMSO from GRwt cells (x-axis) and GR3KR/GRwt from DMSO treated cells (y-axis). GR-binding clusters are color coded, C1 (blue), C2 (black)
and C3 (red). (D–F) Comparison of Dex-regulated genes from RNA-seq between (D) DMSO-treated GRwt and GR3KR cells, (E) ML-792- and DMSO-
treated GRwt cells, and (F) ML-792- and DMSO-treated GR3KR cells. (G) Scatter plot representing RNA-seq log2 fold change of ML-792/DMSO from
GRwt cells (x-axis) and GR3KR/GRwt from DMSO treated cells (y-axis). Circle size depicts TPM values. Genes that are significantly regulated by both
ML-792 (adjusted P-value < 0.01 and log2[ML-792/DMSO] > 0.5 or < –0.5) and GR3KR (adjusted P-value < 0.01 and log2[GR3KR/GRwt] > 0.5 or
< –0.5) are highlighted in red (GR SUMOylation regulated genes). Number of GR SUMOylation regulated genes belonging to each sector is shown in
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occupancy of the interactors. For these analyses, we fo-
cused on NCOA1, a GR coactivator that was significantly
GR3KR-enriched in ChIP-SICAP and showed a marked
GR3KR-enrichment in BioID (Figure 3C). We also deter-
mined the chromatin occupancy of corepressor NCOR1
that showed significant enrichment with GRwt in ChIP-
SICAP, but a slight preference for GR3KR in BioID, and
whose recruitment to certain GR-repressed chromatin loci
has been reported to be regulated by the SUMOylation
of the receptor (70,71) (Figure 3C). Lastly, since SUMO2
was significantly GRwt-enriched in ChIP-SICAP cells and
we have observed differences in chromatin occupancy of
SUMO2/3 between in Dex-treated GRwt and GR3KR cells
(13), we determined the occupancy in vehicle-treated cells.
We performed ChIP-seq experiments in HEK293flpGR
and HEK293flpGR3KR cells with specific antibodies in
the presence of Dex or vehicle and compared the ob-
tained NCOA1-, NCOR1- and SUMO2/3-binding profiles
to GRwt and GR3KR cistromes from the same cells (Fig-
ure 4A, Supplementary Figure S6A and B) (13). We first de-
termined Dex-independent and Dex-dependent chromatin
sites for NCOA1, NCOR1 and SUMO2/3 (see Materi-
als and Methods for details). As shown in Supplementary
Figure S9A, chromatin occupancy of these coregulators
and that of SUMO2/3 do not differ between GRwt and
GR3KR cells at the Dex-independent sites, whereas at the
Dex-dependent sites, the NCOA1, but not the NCOR1,
shows a stronger enrichment in GR3KR than in the GRwt
cells. SUMO2/3 in turn shows a stronger enrichment in
GRwt than in GR3KR cells at Dex-dependent sites (13).
Subsequently, we investigated the occurrence of these pro-
teins at individual GRB clusters. As shown in Figure 5A
and B, the Dex-induced recruitment of NCOA1 is sig-
nificantly stronger at C2 and C3 in GR3KR cells com-
pared to GRwt cells, whereas there is no such difference at
C1. In contrast, the occupancy of NCOR1 does not dif-
fer between the GRwt and GR3KR cells at C2, while at
C1 and C3, the occupancy mirrored the preferred binding
of GRwt and GR3KR, respectively (Figure 5A, C), with
NCOR1 being more enriched at C1 in GRwt cells and at
C3 in GR3KR cells. Also, the occurrence of SUMO2/3 at
C1 and C3 mirrored the binding preference of GRwt and
GR3KR. Thus, the enhanced interaction of GR3KR with
NCOA1 in our proteomic assays is in line with increased
Dex-induced recruitment and co-occupancy of NCOA1 at
the GRBs in GR3KR-expressing cells in our genomic as-
says. Since the chromatin occupancy of GR3KR is higher
than GRwt at most GRBs, this could contribute to the
differential co-occupancy of NCOA1 at these sites. How-
ever, the NCOR1 in turn occupies the GRBs in GRwt- and
GR3KR-expressing cells in a similar manner, suggesting
that the GR-NCOR1 interaction at the genome-wide level
is not generally influenced by the SUMOylation status of
the GR.
Since NCOA1 and SUMO2/3 at C2 sites show an op-
posing enrichment between GRwt and GR3KR cells, the
higher chromatin occurrence of SUMO2/3 could poten-
tially be associated with the lower occurrence of NCOA1 at
the GRwt-occupied C2 sites. We therefore cross-compared
the differences in the chromatin occupancy of SUMO2/3
to the differential binding of NCOA1 between the GRwt
and GR3KR cells (Supplementary Figure S9B and C).
However, the comparison indicated no simple link between
the opposing enrichment of NCOA1 and SUMO2/3 at
C2 GRBs (Supplementary Figure S9C). The above data
suggest that the GR SUMOylation, not the occurrence
of SUMO2/3 at GRBs per se, hampers the Dex-induced
recruitment of NCOA1 onto chromatin. To complement
this notion in live cells, we performed fluorescence recov-
ery after photobleaching (FRAP) experiments. Longer res-
idence times of GR on chromatin measured by FRAP cor-
relate with greater transcriptional output (72), and activa-
tion of GR can increase the residence time of NCOA2 (73).
However, depletion of endogenous NCOA2 does not im-
pact the residence time of GR. We transfected HEK293
cells with mCherry-tagged GRwt or GR3KR and EGFP-
tagged NCOA1 in the presence of Dex. In keeping with
the interaction between the GR and the NCOA1, FRAP
assays showed that the half-recovery times of both recep-
tor forms significantly increased in the presence of an ex-
cess of NCOA1 (Supplementary Figure S9D and E). More
interestingly, NCOA1 was significantly more potent in in-
creasing the half recovery time of GR3KR than that of
GRwt. On the other hand, the half-recovery time did not
significantly change between the receptor forms in the ab-
sence of NCOA1, and NCOA1 showed no difference in
its half recovery in the presence of GR3KR compared to
that of GRwt (Supplementary Figure S9F and G). Our
live cell data thus support our proteomic and ChIP-seq
data showing enhanced association of NCOA1 with the
SUMOylation-deficient GR.
Activated GR regulates chromatin accessibility
Our unbiased proteomic data indicate a prominent recruit-
ment of different chromatin remodeling proteins by the
GR including SMARCA2 (BRM) and DPF2 members of
the BAF complex and other remodelers (e.g. BRD2 and
CHD1) (Figure 3, Supplementary Table S1). Notably, the
BAF complex has been previously associated with the ac-
tion of GR on chromatin (74), where GR at many closed
chromatin sites can recruit the BAF complex to GRBs to
induce opening of chromatin (41,75,76). Other chromatin
remodeling complexes have not been extensively studied for
GR; however, the majority of enhancers harbor the activity
of two or more chromatin remodeling complexes (77).
To assess the enhanced interaction of GR3KR with chro-
matin remodeling complexes, we investigated the chromatin
accessibility by ATAC-seq (78) (see Methods for details). In
both GRwt and GR3KR cells, we detected ∼300 000 open
chromatin sites (Supplementary Figure S10A) which en-
compassed ∼270 000 sites unresponsive to Dex (DexUN).
The DexUN chromatin sites were the most accessible re-
gions (Supplementary Figure S10C), being highly enriched
at promoters (Supplementary Figure S10B) and showing
the presence of several histone marks associated with active
transcription (Supplementary Figure S10H–J). These open
chromatin sites most likely represent the cell type-specific
chromatin landscape of the HEK293 cells (51,79). Inter-
estingly, Dex exposure resulted in a varying degree of in-
crease and decrease in the number of open chromatin sites
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Figure 5. Recruitment of NCOA1, but not NCOR1, to chromatin is influenced by SUMOylation status of GR. (A) Heat maps showing GR, NCOA1,
NCOR1 and SUMO2/3 ChIP-seq profiles from HEK293flpGRwt (wt) and HEK293flpGR3KR (3KR) cells in the presence and absence of Dex. Each
heat map represents ±1 kb around the center of the GR peak. C1 represent GRwt preferred, C2 shared, and C3 GR3KR preferred binding sites. Only
top 10 000 sites (top 10k) are shown for C2. Binding intensity (tags per bp per site) scale is noted below on a linear scale. All heat maps are normalized
to a total of 10 million reads, and further to local tag density. (B–D) Box plots representing normalized log2 tag density of Dex/EtOH for (B) NCOA1
(C) NCOR1 and (D) SUMO2/3 at C1 (blue), C2 (black) and C3 (red) sites. P-values were calculated using unpaired two-sample t-test. All box plots are
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tronic regions (Supplementary Figure S10B). The major-
ity of Dex-induced open chromatin sites were shared be-
tween GRwt and GR3KR cells (DexUP-shared), but there
was a clear cluster of sites where binding of GR3KR in-
duced significantly more opening of chromatin than that of
GRwt (DexUP-3KR) (Supplementary Figure S10C). At the
DexUP-3KR sites, a robust redistribution of H3K4me2 en-
richment was visible after Dex treatment only in GR3KR
cells, whereas at the DexUP-shared sites, a robust redistri-
bution of H3K4me2 enrichment was visible after Dex treat-
ment in both cell lines (Supplementary Figure S10J). We
also observed that Dex exposure closes a smaller number
of open chromatin sites differently in GRwt cells (DexDN-
wt) and GR3KR cells (DexDN-3KR) (Supplementary Fig-
ure S10C). Examples of genome browser tracks of different
types of open chromatin sites are shown in Supplementary
Figure S11A-E.
To gain insight into these different types of open chro-
matin sites, we performed de novo motif analyses (Supple-
mentary Table S4). Analysis of enriched motifs indicated a
clear separation of different open chromatin clusters (Sup-
plementary Figure S10D). DexUN and DexDN open chro-
matin sites showed enrichment for bZIP motifs, such as
AP-1, while their enrichment was low or absent at DexUP
open chromatin sites (Supplementary Figure S10D). CTCF
motifs were also highly enriched at DexUN sites. Bind-
ing of both CTCF and ATF2 (bZIP containing TF) was
enriched at DexUN sites (Supplementary Figure S10E–
F). DexDN sites also display enhanced binding of ATF2.
DexUP open chromatin sites in turn showed a strong en-
richment for NR3C-type motifs, such as GRE (Supple-
mentary Figure S10D). These motifs were also enriched
at DexUN sites, which is indicative of GR binding occur-
ring at pre-accessible chromatin sites. The binding of GRwt
and GR3KR can be observed at DexUP sites (Supplemen-
tary Figure S10G), clearly illustrating the active role of
GR in remodeling of new open chromatin sites. Our chro-
matin accessibility data also suggest that the GR, especially
its SUMOylation-deficient form, induces opening of com-
pacted chromatin sites through the recruitment of chro-
matin remodeling factors.
SUMOylation-deficient GR is more efficient at opening chro-
matin
The proteomics, ChIP-seq and ATAC-seq analyses suggest
that the GR3KR is more efficient at promoting chromatin
accessibility through its increased interaction with chro-
matin modifiers. To gain more insight into this, we focused
on the chromatin accessibility changes at the GRB clusters
defined in our ChIP-seq data, (compare Figure 4A, Supple-
mentary Figure S6A and B). The C1 is the most accessible
of the three clusters (C1–C3) before Dex exposure, which
is reflected in the higher level of H3K4me2 in C1 than in
C2 or C3 (Figure 6A–C). The C3 in turn shows lower en-
richment of H3K27ac and higher enrichment of H3K9me3
than the C1 or C2 (Supplementary Figure S12). Further-
more, the C1 was more pre-accessible in GRwt cells than in
GR3KR cells, possibly explaining the preferred binding of
GRwt to this cluster (Figure 6B, D). This is likely, since ML-
792 does not inhibit GRwt binding to these sites. The C3,
in turn, shows very low pre-accessibility, but the binding of
GR3KR efficiently increases the accessibility of this cluster
(Figure 6A, B and D), whereas GRwt has only a very weak
effect to the accessibility of these sites. These results are mir-
rored by the H3K4me2 enrichment, wherein a clear redistri-
bution after Dex treatment is observed only in GR3KR cells
(Figure 6C). Interestingly, at the C2, the pre-accessibility
does not differ between the cell lines, but also in the C2, the
binding of GR3KR increased chromatin accessibility sig-
nificantly more than that of the GRwt (Figure 6B, D). These
results further strengthen the notion that, although both re-
ceptor forms bind to the same sites, the GR3KR can inter-
act more avidly than the GRwt with chromatin regulators
to open chromatin.
Due to the above observations, we sub-divided C2 sites
based on their pre-hormone accessibility to pre-accessible
and de novo sites (Supplementary Figure S13A, E–F). Pre-
accessible sites are open, while de novo sites remain closed
(i.e. contain no Tn5 insertions) prior to hormone exposure.
The stronger potential of GR3KR in increasing chromatin
accessibility is seen both at the pre-accessible and at the
de novo sites, with a clearer difference at the de novo sites
(Supplementary Figure S13B, E–F). We also assessed the
binding of NCOA1 at C2 pre-accessible and de novo sites,
which showed that this coactivator was significantly more
abundant with GR3KR than GRwt only at de novo sites
(Supplementary Figure S13C, E–F). This was mirrored by
the enrichment of H3K4me2, wherein a clear difference be-
tween GR3KR and GRwt was seen only at de novo sites
(Supplementary Figure S13E and F). NCOR1, however, did
not show a significant preference for either receptor form
at C2 pre-accessible or de novo sites (Supplementary Fig-
ure S13D–F). These results reveal that in comparison to
the GRwt, the GR3KR is especially efficient in recruiting
NCOA1 and regulating chromatin accessibility at closed
chromatin sites.
The target gene-selective effects of GR SUMOylation
in the modulation of chromatin accessibility, coactivator
NCOA1 recruitment and target gene expression are high-
lighted in two examples of GR target loci in Figure 7: PER1
locus is similarly Dex-regulated by GRwt and GR3KR, with
both receptor forms binding to pre-accessible and de novo
chromatin sites. Both receptor forms can recruit NCOA1
to the chromatin and induce the expression of PER1. In
contrast, only GR3KR binds to enhancers at IRS1 locus,
increasing its chromatin accessibility, recruiting NCOA1 to
the enhancers, and resulting in Dex induction of the expres-
sion of the locus. Fittingly, the binding of GRwt to the IRS1
locus is rescued by the inhibition of SUMOylation, which
also results in increased the expression of the locus (Figure
4G).
DISCUSSION
Signal-activated TFs, such as NRs, adopt several modes of
action for binding to chromatin (80). At the heart of these
modes is the NR-mediated recruitment of a diverse group of
proteins known as coregulators. However, systematic anal-
yses of GR-centered chromatin protein networks have been
scarce in the NR field. RIME (Rapid Immunoprecipita-
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Figure 6. SUMOylation regulates the pioneer-like activity of GR in chromatin opening. (A) Heat maps showing GR ChIP-seq and ATAC-seq data from
HEK293flpGRwt (wt) and HEK293flpGR3KR (3KR) cells in the presence and absence of Dex. Each heat map represents ±1 kb around the center of
the GR peak. Binding intensity (tags per bp per site) scale is noted below on a linear scale. All heat maps are normalized to a total of 10 million reads,
and further to local tag density. Sites have been sorted by GR signal, with the strongest GR signal on top. (B) Aggregate plots of ATAC-seq data for C1
(left), C2 (middle), and C3 (right) in GRwt (top, blue) and GR3KR (bottom, red) cells. Aggregate plots represent ±1kb around the center of the accessible
region and are normalized to a total of 10 million reads, and further to local tag density. (C) Aggregate plots of H3K4me2 ChIP-seq data in the presence
or absence of Dex for C1 (top), C2 (middle), and C3 (bottom) sites. Aggregate plots represent ±1kb around the center of the GR-binding site. Data are
normalized to a total of 10 million reads, and further to local tag density. (D) Box plots representing normalized log2 tag density of ATAC-seq data at
C1 (left), C2 (middle) and C3 (right) sites. P-values were calculated with One-way ANOVA with Bonferroni post hoc test. All box plots are normalized to
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Figure 7. Model examples of GR target loci differentially regulated by GR SUMOylation. Example of genome browser tracks of PER1 (left) and IRS1
(right) loci showing GR ChIP-seq, ATAC-seq, NCOA1 and SUMO2/3 ChIP-seq data from GRwt and GR3KR cells. PER1 is Dex induced in both cells.
IRS1 is Dex induced only in GR3KR cells. Dex induction of IRS1 is increased in GRwt cells upon ML-792 treatment. PER1 loci harbor two GR binding
sites, one at pre-accessible and one at de novo chromatin site. GRwt and GR3KR can bind to both sites and recruit NCOA1. At de novo site, both receptor
forms induce chromatin accessibility. IRS1 locus harbors two GR3KR specific binding sites all de novo chromatin sites. GR3KR induces the recruitment
of NCOA1 and chromatin accessibility at these sites. GRwt is able to bind to these sites upon ML-792 treatment.
baric labelling has been successfully applied to identify pro-
tein interactions of estrogen receptor alpha and other TFs
in breast cancer cells (81,82). Moreover, GR interactome
has been recently investigated by ChIP coupled with MS
(ChIP-MS) in mouse liver and mouse embryonic fibrob-
lasts (83). Here, we utilized ChIP-SICAP (18), a novel pro-
teomic methodology, to cast new light to the protein asso-
ciations and chromatin function of GR, an important NR
and drug target that has been widely studied for decades. We
complemented our ChIP-SICAP data with biotin proxim-
ity mapping of the GR interactome, analysis of SUMO2/3-
modified proteins as well as with genome-wide ChIP-seq
and ATAC-seq data from the same cellular background to
show that coregulator recruitment and chromatin openness
induced by glucocorticoid-bound GR is influenced by the
SUMOylation status of the receptor. Furthermore, ChIP-
seq and RNA-seq analyses with SAE inhibitor ML-792 val-
idate the role of GR SUMOylation in these events. Our data
exemplify how a post-translational modification can fine-
tune the response of a signal-activated TF.
Our ChIP-SICAP identifies proteins binding either to
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chromatin protein interactome of hormone-activated GR
includes expected NR coregulators, e.g. coactivators EP300,
NCOA2 and NCOA6, and corepressor NCOR1, but also
proteins not previously linked to GR action. The latter
group includes chromatin-looping associated factors YY1
and cohesin subunits SMC1A and SMC3. In keeping with
the notion that most of the NR coregulators function as
large multi-protein complexes (5,6), we also identify a num-
ber of BAF, CHD and NCOR complex components as
chromatin partners of the GR (see Supplementary Table
S1 for all hits). The biological relevance of our interactome
data is highlighted by the fact that a marked number of the
identified GR’s chromatin partners significantly affect the
glucocorticoid sensitivity of B-ALL cells (19). Examples of
these chromatin partners are CREBBP, EP300, ARID1A,
CHD1, NCOA1, NCOR1 and SUMO2. Our GR chro-
matin interactome thus forms an important resource for the
NR field in parallel with other recent GR interactome stud-
ies (21,84–86). Our work also shows that ChIP-SICAP is a
powerful novel tool for identifying NR on-chromatin inter-
actomes.
The two main SUMO2/3-modified lysine residues of GR
reside at its N-terminal transactivation domain (20). Other
studies have also shown that GR activity is regulated by syn-
ergy control motifs that overlap with the SUMOylation sites
(87,88). These lysines may be targeted also by ubiquitina-
tion (89), but glucocorticoid has not been shown to promote
the latter modification. Our analyses indicate that conjuga-
tion of endogenous SUMO2/3 to the GR is triggered by
binding of glucocorticoid to the receptor. In addition, our
previous re-ChIP analyses indicate the simultaneous pres-
ence of SUMO2/3 and GR and GRBs (13). We have shown
that mutating these two SUMOylation sites (as well as a
third site at the LBD) leads to a SUMOylation-defective
GR that binds more prevalently to chromatin and harbors a
distinct chromatin-binding pattern from the SUMOylation-
competent receptor (13). Moreover, general inhibition of
SUMOylation enables the SUMOylation-competent GR to
bind to and regulate a striking number of chromatin sites
and target genes otherwise bound and regulated merely by
the SUMOylation-deficient GR, thus verifying that the be-
havior of the GR3KR in binding to chromatin and regula-
tion of genes is causally linked to the GR SUMOylation.
Although the SUMOylation inhibitor did not phenocopy
all the differences between the SUMOylation-competent
and -deficient GR, several of the remaining differences can
be attributed to ML-792 inhibiting not only the SUMOy-
lation of GR but also that of other proteins. This is
likely, since SUMO1 and SUMO2 are associated with GR-
occupied chromatin and many of the GR-interacting pro-
teins are also modified by SUMOs. Interestingly, ChIP-
SICAP uncovered a large group of protein associations in-
fluenced by the GR SUMOylation status. The SUMOyla-
tion sites of GR widely curbed the receptor’s association
with of a variety (∼100) of proteins, including the well-
established coactivator NCOA1, chromatin remodelers (e.g.
SMARCA2, BRD2, CHD1) and TFs (e.g. JUN and ATF3
from the AP-1 complex). Our genome-wide data showing
that SUMOylation-deficient GR recruits NCOA1 to GRBs
more efficiently than the wild-type receptor support our
proteomic results. Furthermore, our live imaging data of
GR–NCOA1 interaction are in line with our proteomic and
genomic data; in the presence of NCOA1, the half recov-
ery is slower with GR3KR than with GRwt. However, the
depletion of endogenous NCOA2 does not impact the res-
idence time or bound population of GR in single-molecule
imaging experiments (73). Since single-molecule imaging
mainly estimates stationary/bound molecules, while FRAP
mostly assesses diffusing molecules, the differences between
GR3KR and GRwt in the presence of an excess NCOA1
could be due to altered diffusion kinetics of the receptor.
In addition, we cannot exclude the possibility that the ob-
served difference in the chromatin interaction and recruit-
ment of NCOA1 in part reflects increased association of
SUMOylation-deficient GR with chromatin. Interestingly,
aurora kinase B (AURKB), for which Poulard and col-
leagues have identified a non-canonical role in the regula-
tion of glucocorticoid sensitivity of B-ALL cells (19), was
also enriched with the SUMOylation-deficient GR. More-
over, SUMOylation pathway components were also among
the top genes differentially expressed, overexpressed, in B-
ALL patients at relapse versus their diagnosis stage (19),
suggesting a link between enhanced SUMOylation and re-
lapse or treatment resistance.
Somewhat unexpectedly, there were only a few well-
recognized NR coregulators, such as coactivator NCOA6
(AIB3) and corepressor NCOR1, among the proteins pre-
ferring the SUMOylation-competent GR in ChIP-SICAP
analysis. However, the latter group interestingly encom-
passed IRF2BP2, ZNF536, ZNF703 (NLZ1) and BAZ1A
(ACF1) that are chromatin proteins implicated in NR-
regulated transcriptional repression (90–93) and thus po-
tentially capable of repressing GR at enhancers. Recent
studies suggest that the SUMOylation of GR is required
for the formation of NCOR1-containing repressive com-
plex for tethered and negative GRE-mediated transrepres-
sion (70,71), or for repression of estrogen receptor signaling
by GR (94). However, the genome-wide co-occupancy of
NCOR1 at the GRBs is not affected by the SUMOylation
status of GR. The inconsistencies between ChIP-SICAP,
BioID, and ChIP-seq data with NCOR1 imply a complex
nature of the interaction between the SUMOylation status
of GR and the corepressor. Thus, the reported effect of GR
SUMOylation on the NCOR1-containing complex might
be restricted to a few specific loci.
Enrichment of chromatin remodeling factors was one
of the differences between the chromatin interactome of
SUMOylation competent and that of the modification
deficient GR. The factors more avidly interacting with
the SUMOylation-deficient GR included several subunits
of the BAF complex and several CHD family members
as well as BRD2. In addition, topoisomerase II homo-
logues, TOP2A and TOP2B as well as poly(ADP ri-
bose)polymerase 1 (PARP1), preferentially associated with
non-SUMOylated GR. Interestingly, TOP2B and PARP1
have been shown to be required for BAF mediated tran-
scriptional activation (95), while BRD2 influences gluco-
corticoid sensitivity of B-ALL cells (19,96). While some
CHD proteins have been associated with GR-regulated
gene expression only recently (97), the interplay between
GR and BAF complex, especially its catalytic subunit
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GR-regulated enhancers are well known (75,76). In addi-
tion, SMARCA2 (BRM) has been shown to be important
for the regulation of GR target genes (99,100). Besides bind-
ing to pre-accessible, open chromatin sites, GR can bind
to closed nucleosomal sites, recruiting BAF complex to
evict nucleosomes and promote an open chromatin state
(75). We also observe a similar pioneer factor-like mode
of GR, when the receptor binds to closed chromatin sites
and thereby increases their accessibility. The pioneer-like
activity is particularly notable with the non-SUMOylated
receptor, as it was able to access to a large subset of closed
chromatin sites that are inaccessible to SUMOylated GR.
Importantly, the effect of SUMOylation status on the in-
teraction of the receptor with chromatin remodeling fac-
tors is reflected in our chromatin accessibility data, also on
pre-accessible sites, and gene expression data, showing that
the SUMOylation-deficient GR is more potent in opening
of chromatin at glucocorticoid-regulated enhancers and in-
ducing expression of their target loci. Moreover, the pio-
neer factor-like potential of non-SUMOylated GR might
be potentiated by the enhanced interaction with topoiso-
merases, as TOP2 synergizes with BAF complex to trans-
form facultative heterochromatin into more accessible chro-
matin (101). Finally, since SUMOylation on chromatin can
act as a general stabilizer of chromatin states, controlling
gene programs that need to be rewired during differentia-
tion processes (102), SUMOylation of TFs directing differ-
entiation processes could control their capacity to interact
with the chromatin in a manner similar shown here for GR.
In the case of a ‘classic’ pioneer TF, FOXA1, SUMOyla-
tion indeed has been demonstrated to restrict its pioneering
activity on chromatin (103).
Recent ChIP-seq studies have addressed the
role of SUMOylation of three human TFs, MITF
(microphthalmia-associated transcription factor), GR,
AR, and a yeast TF Sko1. In all cases, SUMOylation-
deficient forms of these TFs displayed significantly en-
hanced interaction with chromatin by binding to numerous
additional sites compared to their wild-type counterpart,
thus suggesting a conserved role for the modification in
restricting TF binding to chromatin (13–15,17). Most of the
SUMO-targeted TFs, including the above listed ones, are
endogenously modified only to a sub-stoichiometric level.
The reason why a relatively small pool of SUMOylated TF
can cause obvious effects on the transcriptional activity of
TFs is likely to be due to the dynamic nature of the mod-
ification, i.e. rapid cycles of conjugation-deconjugation.
Even though the equilibrium might lie on the side of the
unmodified TF, a large portion of the pool of a given TF
might be affected by SUMOylation in a short window of
time. SUMOylation can lead to recruitment of repressive
factors, and a repressive state can remain even after SUMO
is deconjugated from the TF. Alternatively, SUMOylation
can trigger a chain of events, leading to formation of a
relatively stable complex. These complexes may remain
even after deconjugation of SUMO. In both cases, the TF
needs to be modified only for a short period of time. Based
on the genome-wide chromatin-binding data of AR, GR,
MITF and Sko1, Rosonina recently proposed a model for
the role of TF SUMOylation in fine-tuning TF-binding
site selection (16). According to this model, DNA binding
triggers SUMOylation of TFs, which in turn alters their
chromatin occupancy. However, the actual mechanism un-
derlying the SUMOylation-altered chromatin occupancy
of TFs has remained elusive. The DNA-TF interaction per
se does not appear to be affected by the SUMOylation. The
modification may in principle affect chromatin off-rate or
nuclear mobility of its target TF, but these notions hardly
explain the locus-selective effects of the SUMOylation
on the TF. In the case of GR and AR, SUMOylation
is induced by binding of their cognate hormones and
promoted by PIAS proteins, such as PIAS1 and PIAS2
that are regulated by phosphorylation via other signaling
pathways (11,20,104,105). Our data complement the
model. We uncover that the hormone-triggered SUMOy-
lation modulates the chromatin protein network of GR,
curbing its protein-protein interactions with a number of
prominent coregulators. Our live cell imaging data lend
support to the notion that the recruited coactivator(s)
can stabilize the association of GR with chromatin. The
enhanced interaction of SUMOylation-deficient GR in
particular with chromatin remodelers is likely to contribute
to its promiscuous chromatin occupancy. We speculate
that a similar mechanism might operate with many other
SUMOylated TFs. Our study additionally foreshadows
a concept that may apply more generally to TFs whose
activity is regulated by covalent modifications that in turn
modulate protein interaction networks on chromatin.
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